What Signpath Pharma does

Signpath Pharma is a clinical-stage biotechnology company headquartered in Sandy, Utah, founded in 2007 by Bruce Meyers. The company operates two proprietary technology platforms: LipoCurc, a liposomal curcumin formulation for cancer treatment, and the CorreQT platform, which develops cardiac-safe versions of existing drugs by eliminating drug-induced arrhythmia and cardiac muscle damage. The company has no commercial revenue and operates on prior capital raised through equity funding rounds.

LipoCurc, the lead clinical asset, is a proprietary intravenous liposomal curcumin formulation licensed exclusively from MD Anderson Cancer Center. The product achieves blood curcumin levels more than 1,000 times higher than oral dosing without cardiotoxicity. It has completed Phase 1a/1b trials in 70 human subjects demonstrating no cardiac toxicity and preliminary efficacy in heavily pre-treated cancer patients. A Phase 2 trial in first-line glioblastoma treatment is enrolling at Johns Hopkins University Hospital, with additional sites planned. The asset received FDA Orphan Drug Designation in 2025 and the company has submitted Fast Track and CNPV designation requests. Additional mesothelioma trials are being prepared, and working relationships extend into Canada, Europe, and Asia.

The CorreQT platform, led by compound SPP4040, is a lipid-based oral drug positioned to extend into antibiotics, antipsychotics, and antihistamines beyond its initial oncology focus. The intellectual property estate comprises more than 15 issued US patents with corresponding international filings covering cardiac arrhythmia, cardiomyopathy, and cytokine storm, with protection running through at least 2037, supported by a publication record of 63+ papers. As a micro-cap company with 1-10 employees and approximately $7.3 million in total disclosed funding across three rounds between 2011 and 2016, Signpath's business model is contingent on future capital raises to advance its pipeline toward potential FDA approval, licensing transactions, or acquisition. The company trades on the OTC pink market under ticker SGTH.

Name

Signpath Pharma

Legal name

Signpath Pharma, Inc.

Website

https://signpathpharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Signpath Pharma is a clinical-stage biotechnology company developing LipoCurc, a proprietary liposomal curcumin therapy in Phase 2 trials for glioblastoma, and the CorreQT platform for creating cardiac-safe versions of existing drugs.

Ownership category

akta.pro rank

Product category

Clinical-stage Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Liposomal curcumin formulation
• Cardiac safety drugs
• Glioblastoma therapeutics
• Cancer supportive care
• Clinical stage biotechnology

Headquarters

HQ city

Quakertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. LipoCurc (Liposomal Curcumin): Revenue from proprietary liposomal curcumin product for cancer treatment, currently in Phase 2 clinical trials for glioblastoma and being prepared for mesothelioma trials.
2. CorreQT Platform Compounds: Revenue from cardiac-safe drug formulations (SPP4040 and other compounds) addressing the cardio-protective agent market for cancer supportive care.
3. Cancer Supportive Care: Cardio-protective agent intended for use alongside chemotherapy agents, positioned similar to Amgen's Neupogen model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Signpath Pharma is a clinical-stage pharmaceutical company that develops proprietary drug products built around two technology platforms. The first is LipoCurc, an intravenously administered liposomal curcumin formulation for cancer treatment (Phase 2 for glioblastoma). The second is the CorreQT platform, which creates cardiac-safe versions of existing drugs; its lead compound SPP4040 is an oral lipid-based drug designed to eliminate chemotherapy-induced cardiac arrhythmia and cardiac muscle damage.

Product overview

Signpath Pharma is a clinical-stage pharmaceutical company with two key product programs. The primary clinical product is LipoCurc, a proprietary liposomal curcumin formulation administered intravenously for cancer treatment, which has completed Phase 1a/1b trials and is now in Phase 2 for glioblastoma. The second is the CorreQT technology platform, which uses a patented approach to create heart-safe versions of existing drugs; the lead compound from this platform is SPP4040, an oral lipid-based drug in development for cardiac protection during chemotherapy.

Differentiator

Problem solved

Functional benefit

Brands

• LipoCurc™: Proprietary liposomal formulation of curcumin administered intravenously for cancer treatment, particularly glioblastoma and mesothelioma.
• CorreQT

Products and services

• LipoCurc LipoCurc is a proprietary liposomal formulation of curcumin administered intravenously for the treatment of cancer. It achieves curcumin blood levels over 1000 times greater than standard oral curcumin without cardiotoxicity. It has completed Phase 1a and 1b trials in 70 human subjects and is currently enrolling in a Phase 2 trial for first-line treatment of glioblastoma at Johns Hopkins University Hospital. It is also being prepared for mesothelioma trials.
• CorreQT Platform

Quantifiable outcome

• Phase 1 trials: No cardiac toxicity observed in 70 human subjects
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• M.D. Anderson Cancer CentercoreStrategic or Co-development PartnerLipoCurc was developed by researchers at M.D. Anderson Cancer Center and exclusively licensed to Signpath. This foundational research partnership established the company's lead product.
• Johns Hopkins University HospitalcoreStrategic or Co-development PartnerPhase 2 clinical trial site for first-line treatment of glioblastoma. Signpath is working to expand the number of clinical sites.
• International Research PartnersminorStrategic or Co-development PartnerWorking relationships with labs, hospitals, and other companies in Canada, Europe, the U.S., and Asia for research and development activities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Medicenna Therapeutics: Clinical-stage biotech developing MDNA55 for recurrent glioblastoma. Similar stage, similar indication focus, and similar small-cap biotech profile with novel mechanism approaches to CNS tumors.
• Mustang Bio: Clinical-stage company developing MB-101 (CAR-T) for glioblastoma. Directly comparable as a small-cap clinical-stage company pursuing novel therapies in glioblastoma with similar trial-stage risk profile.
• Kazia Therapeutics: Australia-based clinical-stage oncology company developing paxalisib for glioblastoma. Directly comparable to Signpath as a small-cap, clinical-stage biotech focused on novel glioblastoma therapeutics with similar regulatory pathway considerations.
• Kintara Therapeutics: Clinical-stage oncology company developing VAL-083 (dianhydrogalactitol) for glioblastoma. Comparable small-cap structure with similar Phase 2/3 development stage and indication focus.

Emerging players

• Geron Corporation: Clinical-stage biotech that has pioneered novel oncology mechanisms (imetelstat) with similar small-cap, late-clinical-stage profile and dependence on a single platform technology.
• INOVIO Pharmaceuticals: Clinical-stage biotech with DNA medicines including INO-5401 for glioblastoma. Comparable as a small-cap clinical-stage oncology company pursuing novel mechanisms in the same indication.
• Curis: Clinical-stage oncology biotech developing small-molecule targeted therapies. Similar small-cap clinical-stage profile pursuing novel oncology mechanisms across multiple indications.

Broad incumbents

• Bristol-Myers Squibb: Large oncology incumbent with checkpoint inhibitors (Opdivo) targeting PD-1/PD-L1 pathways relevant to LipoCurc's mechanism. Represents the broader immunotherapy landscape where LipoCurc's immunomodulatory claims would compete.
• Novocure: Commercial-stage company with FDA-approved Tumor Treating Fields (Optune) for glioblastoma. Represents the established standard-of-care that LipoCurc would compete against in the same indication.

Others

• Amgen: Large biopharmaceutical company explicitly cited by Signpath as the model for cancer supportive care (Neupogen). Represents the commercial reference for the supportive-care positioning of Signpath's CorreQT platform.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/signpath-pharma-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Signpath Pharma